During low oxygen tension, sicklehemoglobin (HbS) polymerizes into multistranded fibers 1,2 that force red blood cells (RBC) into crescent (sickle) shapes. 3 In 1949 Pauling et al 4 showed that HbS was electrophoretically distinct from normal human adult hemoglobin (HbA). Using peptide "fingerprinting" techniques, Ingram 5 traced the electrophoretic differences to a single substitution of valine (HbS) for glutamic acid (HbA) at position 6 of the β-chain. This sickle cell mutation, a single nucleotide substitution (GAG to GTG), leads to disease in homozygous individuals (HbSS) and is the most common genetic disorder that affects black Americans. This presence of a hydrophobic side chain (on valine) substitutes for a polar residue (on glutamic acid) and occurs on the surface of the first (A) α-helix in the 3-dimensional structure of HbS. 6 It creates an accessible apolar (donor, sticky site) region complementary to a crevice (acceptor) between the E and F helices in the β-chain of an antiparallel HbS molecule in a growing fibril. Key contact residues in the acceptor site (the hydrophobic complementarity site) are phenylalanine 85 (Phe 85) and leucine 88 (Leu 88) from the F helix. Together, the donor and acceptor in the reference β-chain interact with 2 other HbS molecules in offset positions to provide the major condensation events leading to double-stranded helical stacks of indefinite length (Fig 1, A) . As these polymers grow, there are ample opportunities for other free donor and acceptor sites on the surfaces of the strands to interact and both lengthen and broaden the fibrils. 7 Eventually, the bundles of fibrils distort the erythrocytes into sickle shapes. The hemoglobin fiber formation is time-and oxygen-concentration dependent. 8 It is estimated that 1 of every 600 black Americans is affected by sickle cell anemia 9 and that 1 of every 24.5 individuals are carriers and heterozygous. Patients experience episodes of ischemia 10 when small blood in helix A of the β-chain of sickle cell deoxyhemoglobin (HbS) with an acceptor site at the comer of helices E and F of another HbS molecule. Side chains of Phe 85 and Leu 88 are shown in the acceptor site at the EF comer. This interaction is the primary structural event in the sickling of erythrocytes in sickle cell anemia. The model was constructed with the program MOLMOL 43 from atomic coordinates of deoxygenated HbSS in the Protein Data Bank. Lower panel, Similar model but with aspartame inserted into the acceptor site at the EF comer of an HbS molecule. In this speculative arrangement, helix A with its valine β6 is represented as a virtual model displaced from its sickling position by aspartame. vessels are occluded by misshapen cells. The clinical manifestations of the disease are well-known and include vasoocclusive pain, 11 functional asplenia, 12 priapism, 13 and stroke. 14, 15 The impetus for investigating the clinical applications of aspartame was initially provided by x-ray analysis of crystalline complexes of the ligand with antibody fragments. 16, 17 Aspartame blocks hydrophobic active sites in the human immunoglobulin (Mcg and Sea) light-chain dimers (referred to as Bence Jones proteins), murine antisweetener Fab (antigen-binding fragments), and human immunoglobulin M rheumatoid factors. Two molecules of the ligand are bound in the cavity of the Mcg dimer, 1 on each monomer. The hydrophobic portion of the ligand (ie, the phenylalanine methyl ester) enters first and interacts with aromatic phenylalanine and tyrosine residues lining the binding sites. This interaction is shown schematically in Fig l, B. Steric interference with the binding of the valine side chain should affect the capacity for the helical stacking of the hemoglobin molecules and interfere with the deformations in the shapes of the RBCs in sickle cell anemia. Compared with antibody surrogate receptors and cyclooxygenase active sites, the EF acceptor site in HbS appeared to be a smaller and simpler target for blockade by aspartame. Theoretical and practical groundwork for this study was provided earlier by the production of peptide mimics for the valine donor region and the EF acceptor pocket. [18] [19] [20] Aromatic residues such as phenylalanine were favored constituents of the peptides (including Asp-Phe), acting as inhibitors of the gelation (polymerization) of HbS. As models for other inhibitors, phenylalanine alone 21 and Phe-Lys were slowly and reversibly taken up by erythrocytes. 22 The effects of aspartame on HbS solubility appear to have been adequately addressed for its nonesterified version (Asp-Phe) by Noguchi et al. 20 Asp-Phe increases the HbS solubility to about the same extent as phenylalanine alone. With reference to binding activity, the immunoglobulin M proteins selected to test aspartame also tolerated the extra negative charge on Asp-Phe without demonstrable losses in affinity (eg, immunoglobulin M rheumatoid factors: Drs Paul Ramsland, Morris Reichlin, and Allen Edmundson 23 ). We have emphasized aspartame more than Asp-Phe because it is inexpensive, available in large quantities, palatable to human subjects, and generally recognized as safe. The differences in structure are shown in Fig  2. Our speculation that aspartame, acting as a possible glucose analog, would be rapidly transported into the cells was based on the RBC membrane transporter functions reported by Carruthers. 24 Because this transporter is sensitive to calcium concentration, 24 the interdiction of aspartame effects by ethylenediaminetetraacetic acid (EDTA) through chelation of calcium was recognized as a potentially important variable in the current project. We made special efforts to ensure that all blood samples were obtained with heparin as the anticoagulant instead of EDTA.
METHODS
In vitro studies. Blood samples were obtained from 20 pediatric subjects with documented HbSS disease who were receiving phlebotomy and chronic transfusion therapy to prevent another stroke. The blood samples were stored in heparinized tubes. Twelve samples were evaluated in vitro by the standard method for inducing sickling with use of metabisulfite. Eight additional specimens were evaluated after hypoxia induced by metabisulfite, and by 100% argon at 1 atmosphere for 1 hour. "Sickle preparations" were made for untreated blood and for specimens mixed with aspartame (Sigma Chemical Co, St Louis, Mo, lot 16H1016). To the latter specimens, 1 or 2 mg aspartame was added to 1-mL aliquots of whole blood. Slides of sickled cells were prepared by use of the technique of Daland and Castle 25 as modified by the descriptions from Todd and Sanford. 26 Numbers of the sickled and unsickled cells were registered with a hand counter. Counts were made before and after the addition of a drop of untreated or aspartame-containing blood to a 2% metabisulfite solution that was prepared fresh daily. The numbers of sickle cells observed in untreated specimens and treated before exposure to metabisulfite ("baseline count") were subtracted from subsequent counts of untreated or treated samples to eliminate the effect of permanently sickled RBCs. In the statistical treatment of the data, a constant was added to all final tabulated values to eliminate the occasional negative values that arose from baseline subtraction of permanently sickled RBCs. All counts were unblinded and made in triplicate.
Photomicrographs of the treated and untreated metabisulfite or argon preparations were obtained with phase-contrast objectives at 100×. Automated blood cell counts were made on 8 specimens to verify that metabisuifite was not inducing selective hemolysis that had an impact on the counting of the sickle preparations. Comparison testing of the same blood after chelation of Ca 2+ by EDTA was also performed. Numbers of observed sickled cells per hundred counted were subjected to ANOVA. Statistical analysis of preparation counts at 0, 30, and 120 minutes was completed with use of GraphPad PRISM software (GraphPad Software, San Diego, Calif). Comparison hemograms were obtained by automatic techniques performed at a reference laboratory on aliquots of the same specimens that had previously been hand counted.
In vivo studies. Heparinized whole blood specimens were evaluated from 23 additional subjects with anemia who were being monitored for SS, HbS/β°tha-lassemia, or sickle cell disease in the Sickle Cell Clinic. No patients were taking hydroxyurea or were receiving chronic transfusion therapy. Fifteen subjects were homozygous, 3 had HbS/β°thalassemia, and 5 had sickle cell trait. After giving informed consent, patients were randomized to receive a single oral dose of 1.5 mg, 3 mg, or 6 mg/kg aspartame. Aspartame was administered as whole tablets of NutraSweet (19 mg aspartame per tablet; NutraSweet Company, Chicago, Ill). Dosage was determined by the subject's weight, but calculations leading to fractional tablet size were adjusted to the next full tablet. The tablets were administered all together with 30 mL water. Counts of sickled cells/100 RBC were blinded but were otherwise completed as described earlier. Each sickle preparation was also counted by hand and from photomicrographs recorded in the same period. Specimens were examined at 0, 30, 60, 120, 240, 480, and 1440 minutes after administration of aspartame. Baseline subtractions of irreversibly sickled cells were not applied to blinded counts.
Full frame photomicrograph prints (4 × 6 inches) obtained from phase-contrast images at the same magnification were scanned with a Kodak Shaphhot Photo Scanner (Eastman Kodak Co, Rochester, NY). Two individuals reviewed digitized images of the wet preparations. The classification of normal or sickled was registered on the digitized image. Obliquely or vertically oriented RBCs that were difficult to classify were considered normal or sickled after the 2 readers reached agreement on the image classification. Cells that were difficult to classify were consistently less than 5 per photograph. The ratio of sickled to unsickled cells (counted by computer) was recorded for each photo field. Triplicate hand counts and the photo field counts obtained from ScanPro (SigmaScan Pro, Jandel Scientific, San Rafael, Calif) were compared for correlation with GraphPad Prism software. Hemoglobin electrophoresis was performed at a reference laboratory (University of Oklahoma Health Sciences Center).
The technique of Wright and Jenkins 27 was used to perform whole blood viscosity determinations of the baseline and 120-minute specimens from 10 of 23 subjects. These assays were performed at pressures of 20 mm Hg with use of concurrent water and saline controls. Sickling was induced with 2% metabisulfite. Determinations of viscosity of normal whole blood specimens were checked against the reference data of Pirofsky. 28 Viscosity changes were assessed by χ 2 analysis with the GraphPad Prism software. Doseresponse relationships were assessed by a repeatedmeasure ANOVA.
RESULTS
In vitro studies. Counts of the numbers of sickle cells observed in control and aspartame-treated blood samples are given in Table I . In the presence of aspartame, at the final concentrations of 1 mg/mL or 2 mg/mL, the numbers of sickled cells were found to decrease significantly. Photomicrographs of blood samples before and after administration of aspartame are presented in Fig  3. Together, these evaluations reveal that the ability of HbS-containing blood cells to sickle is impaired, as conclusion was affirmed by the use of argon as an alternative hypoxia-inducing substance. These data are not shown. With argon, we found that the numbers of platelets and white blood cells were altered when shown by visual inspection of the photomicrographs and by quantitative analysis of the cell counts. The use of the metabisulfite to induce sickling did not appear to bias the ratio of unsickled cells to sickle cells. This counted with an SE 9000 automatic counting machine (Sysmex, Kobe, Japan). Platelets remained as discrete entities in the presence of argon. They are agglutinated in metabisulfite and are counted as white blood cells in the automatic counting procedure. Although the numbers of platelets and white blood cells change depending on the manner of hypoxia treatment, the number of sickle cells per 100 RBCs remained stable. Moreover, the hemoglobin and hematocrit values were also unchanged (data not shown). A notable result involved the impact of EDTA on sickle cell counts. Blood that had been previously shown to be positively responsive to the antisickling effects of aspartame was unreactive to the compound when EDTA was present. In the absence of EDTA the mean percentage of sickled cells 2 hours after the addition of 1 mg aspartame per milliliter of whole blood was 13.95%, compared with 27.67% in the control preparations. When the aspartame dose was doubled to 2 mg/mL, the mean percentage of sickled cells fell further to 12.08% at 2 hours. This antisickling effect from aspartame shows a change in the number of countable cells. The antisickling effect was detectable for at least 27 hours after the addition of aspartame to the blood specimen. ANOVA from the in vitro testing was statistically significant at P < .0004. Qualitatively, photomicrographs add evidence for the diminution of the sickling by aspartame. Even in nonsickled cells, the hemoglobin distribution visually appears to be nonhomogenious (Fig  3) . In summary, the in vitro data appear to support the concept that formation of sickle cells in the presence of metabisulfite or argon can be inhibited with aspartame.
In vivo studies. Among the 23 patients in the randomized blinded dose-response there were 15 patients with HbSS (homozygous), 3 patients with HbS/β°tha-lassemia, and 5 patients with sickle trait, HbSC. Genotypes were determined by hemoglobin electrophoresis performed at a reference laboratory. Demographic data are shown in Table II . Analysis of mean dose group differences was complicated by the lack of antisickling effects observed in the subjects with sickle cell trait. For example, sickling was unchanged or increased in 5 of 5 HbSC subjects treated with aspartame (Fig 4) . Aspartame decreased sickled RBCs in 15 of 15 SS subjects. Fig 4 shows the dose-response time curves for all data of HbSS and HbS/β°thalassemia subjects. Because all counting was performed in a blinded manner, the presence of increased or unchanged numbers of sickled cells observed in subjects with sickle cell trait provided an unexpected positive control group, as shown in Fig 4. A maximal effect was noted after a dose of 6 mg/kg aspartame, and that effect lasted 8 hours or more. The ANOVA of the HbSS subjects showed a significant difference in countable cells related to time after aspartame administration that was statistically significant (P < .005), with an F ratio of 3.309. The responses of HbS/β°thalassemia subjects to aspartame were similar to the responses of homozygous HbSS subjects and were therefore included with the HbSS data. Viscosity values of whole blood HbSS and HbS/β°t halassemia decreased in the subsets of subjects treated with aspartame (Fig 5) . Subjects within the subset with sickle cell trait showed an increased blood viscosity. As shown in Fig 5, 7 of 7 HbSS subjects in the viscosity testing subset of 10 subjects showed decreases in viscosity for specimens obtained 2 hours after aspartame administration. In the same subset, 3 of 3 subjects with sickle cell trait, HbSC had increased viscosity under the same conditions.
Correlational analysis revealed decreased viscosity associated with decreased numbers of observed sickled cells (data not shown). The second correlational analysis revealed an association between the photo-counted sickle preparations and hand-counted preparations (Fig  6) . Both correlational analyses account for a limited amount of the variability observed in the correlation, but no systematic error in data location relative to the fitted line was observed.
The fitted line (Fig 6) does not pass through zero. One plausible explanation is that the baseline photo fields may have had 4 to 8 countable sickled cells in the photo fields that were not counted by the hand method. Because the photo field counts had mean cell totals of >200, the numbers of counted unsickled cells could reach 100 before a sickle cell was counted. Failure to identify a few cells in the sickle cell category is also a possibility. This was considered to be the most likely explanation. Differences greater than 10 in either hand counts or photo counts would not be explained by the correlation variability. 
DISCUSSION
The "sticky site" produced by the valine substitution in HbS is complemented by the formation of a groove or pocket into which the hydrophobic valine may be bound. 6 It seems important to consider the speculation that the hydrophobic binding domain (the complementarity region) may be able to accommodate the phenylalanine of aspartame, whereas the trailing aspartic acid moiety acts as a large hydrophilic extension that interferes with the approach of competing valine residues.
The upper panel of Fig 1 illustrates the probable insertion of the sticky valine on 1 HbS-β-chain into the acceptor pocket at the EF corner of another HbS molecule. In the lower panel of Fig 1, we show a model that illustrates an interaction between aspartame and the EF complementarity site of HbS. The superimposed "virtual image" of the α-helix that contains valine β6 would be prevented from its deleterious binding to the EF acceptor site by the competing presence of aspartame. An interaction such as this would obstruct sickling. The insight that a functional interruption of intracellular biopolymerization might occur appears to be possible from the results of this study.
Although large quantities of basic information have been accumulated on the structure and function of HbS, the possible treatments for sickle cell disease have remained limited. 9, [29] [30] [31] The management of painful episodes still relies on the use of fluids for hydration 32 and analgesics for pain relief. 32 Recent research has focused on promotion of the expression of HbF because patients with larger amounts of Hb F have been observed to have milder disease courses. 33 Use of hydroxyurea in this way may be responsible for myelosuppression and as-yet undefined long-term effects. 34 Other research strategies in recent years have focused on changing the β-globin gene itself. 9 However, gene transfer therapy remains unavailable and to date only a few patients have a human leukocyte antigen-identical sibling who can act as a bone marrow donor. For most patients, therefore, supportive care with hydration and analgesia remain the mainstay of therapy for pain crises. 9, 32, 35, 36 Although chronic transfusion therapy is effective in preventing further sickling and pain, it is usually reserved for patients who have had catastrophic events, such as strokes, 37 because its use inevitably leads to iron overload. 38 Compensatory chelation therapy 39 is then required to remove the excess iron load.
The data from this study appear to support the concept that fiber formation can be altered with aspartame. Because the changes in observed cell counts may be influenced by subjective bias (from individual interpretations of "what is a sickled cell?"), photomicrographic analysis was performed during the dose-response study to address such questions. These analyses confirm the hand-counted results. Comparisons of specimens prepared with argon and metabisulfite suggest that slight hemolysis occurs with the latter reagent. However, we were unable to show any selective bias attributable to metabisulfite treatment. Obviously, loss of metabisulfite potency could confound the interpreted results. Because metabisulfite solutions were prepared fresh daily, this possibility was excluded by virtue of technical approach. In the blinded trial, special care was taken to ensure the stability of the metabisulfite solutions when baseline and sequential counts were very low and unchanging. For specimens with high baseline counts, we regularly repeated the counting procedures to confirm the potency of the metabisulfite. Those specimens with anomalous time courses were observed to have unusual viscosity increases rather than decreases. At unblinding, the identification of results considered to be anomalous were found to be related to the presence of HbSC disease. Finally, we noted that the photomicrographs taken of treated and untreated sickle preparations were so different that changes could be unambiguously detected. However, we also found that photomicrographs might have been biased by the area chosen to count, the number of overlapping cells, rouleaux, and cell movement in the counting field between counting and photodocumentation. We have no reason to believe the data were sufficiently biased to account for the large changes in hemoglobin behavior and attendant effects on RBC shapes.
Preclinical methods commonly used to validate and measure change in hemoglobin conformation have used elegantly sophisticated analyses of rheology, 40 gelation, 41 and electrophoresis to measure and quantify the change mediated by biochemical alterations. 42 Although they have elucidated the relevant chemistry, these techniques have not helped with the understanding of intracellular delivery of a candidate molecule likely to interdict in the process of sickling and ultimately lead to clinical results. The demonstration of the antisickling properties of L-aspartyl-L-phenylalanine was first made by Noguchi et al 19 and Noguchi and Schechter. 20 The properties of the dipeptide but, apparently, not the methyl ester were appreciated and well documented. Since the US Food and Drug Administration's release of aspartame as a glucose analog, its use as a sweetener has been characteristically limited to low concentrations. Furthermore, its absorption from the intact gastrointestinal tract has previously been considered to be negligible. After the addition of aspartame to whole blood, any intracellular interactions that diminish hemo-globin fiber formation should be microscopically observable and considered attributable to transport of the dipeptide ester across the RBC membranes. Membrane effects and RBC hydration are other factors that need to be evaluated. In vitro testing that preceded the clinical dose-response study suggested that the aspartame effect on HbS fiber formation was abolished by chelation of Ca 2+ by EDTA. This observation strongly suggests that aspartame effects might have been overlooked previously because of the common practice of collecting whole blood in tubes that contain EDTA.
Our studies have been directed at a concentrated presentation of aspartame to absorptive surfaces, tissues, and whole blood. Our goal was directed toward overwhelming the metabolic systems responsible for degradation of aspartame as a prelude to facilitating clinical observations. We recognize that the internal metabolic pathways in RBCs require stable enzymes resistant to proteolysis. If the hydrolysis of an intracellular peptide such as aspartame were also retarded, we might have expected the sweetener to have a protracted effect on sickling. However, the extended duration (27 hours) of observed effect in vitro was still a surprise. This protracted period of activity was repeatedly validated in vivo because decreased sickling of RBCs could be observed for long intervals after patients received oral administration of aspartame.
In summary, aspartame is particularly convenient to use in clinical trials because it is considered to be safe for human consumption. Further tests of its efficacy in limiting clinical events related to sickling of RBCs are clearly warranted, especially in view of the very large benefit-to-risk ratio that accompanies its use.
